Mabwell Bioscience’s 9MW3811 Receives NMPA Approval for Clinical Trials in Oncology and Fibrosis
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...
Fineline Cube
Roche’s Rozlytrek on Track for Priority Review for Pediatric NTRK Fusion Tumor Treatment
The Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Rozlytrek (entrectinib)...
Zelixir Biotech Secures Over RMB 100 Million in Series A Financing for Synthetic Biology Pipeline
Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly...
PathoAI Secures Tens of Millions in Angel Financing for AI-Powered Pathology Solutions
PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI),...
Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the...
MicroPort Endovascular MedTech Announces Private Placement to Fund Innovation and Expansion
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up...
Antengene’s ATG-022 Earns FDA Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based Antengene Corporation Limited (HKG: 6996) has announced that its in-house discovered and developed antibody...
CDE Drafts Proposal on Generic Drug Studies for Varieties without Reference Preparations
The Center for Drug Evaluation (CDE) has released a Notice on the “Generic Study for...
Mural Health Partners with Clinflash to Enhance Patient Payments in Clinical Trials
US-based Mural Health has announced a strategic partnership with China-based Clinflash, both companies specializing in...
Hanx Biopharmaceuticals’ HX009 Receives US IND Approval for Lymphoma Treatment
Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND)...
Clover Biopharmaceuticals Partners with Kyuan Trade for Commercial Launch of AdimFlu-S (QIS) in China
China-based Clover Biopharmaceuticals Ltd (Clover; HKG: 2197) has announced the establishment of a commercial partnership...
Minghui Pharmaceutical Initiates First-in-Human Trial for IGF-1R Antibody Fusion Protein MHB018A
China-based Minghui Pharmaceutical Inc. has announced the commencement of a first-in-human Phase Ia trial for...
Shanghai Ark Biopharmaceutical Partners with WuXi STA for Commercial Supply of Ziresovir
China’s Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has entered into a partnership with WuXi STA,...
China’s NMPA and NHC Tighten Regulations on Tramadol Compound Preparations
The National Medical Products Administration (NMPA) and National Health Commission (NHC) have released a notification...
Sino Biopharmaceutical’s TQ-B3525 Files for Market Approval with CDE
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a market approval filing for its Category 1...
MabPharm’s CMAB007 Receives NMPA Approval for IgE-Mediated Asthma Treatment
Taizhou-based monoclonal antibody (mAb) biosimliars specialist MabPharm Ltd (HKG: 2181) has announced that it has...
Alibaba Health Reports 30.1% Revenue Growth in 2022 Financial Report
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...
Enhertu, HER2-Targeted ADC, Officially Launched in China for Breast Cancer Treatment
Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
BeiGene’s Tislelizumab Approved in China for First-Line Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has been approved...
Bayer’s Copanlisib (Aliqopa) Approved by NMPA for Recurrent Follicular Lymphoma
The National Medical Products Administration (NMPA) has indicated on its website that Bayer’s (ETR: BAYN)...